00 · At a glance

Two pan-RAS drugs showed pancreatic cancer data, both single-arm. Actinogen’s Alzheimer’s trial missed.

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 4 min read

Bookmarks need a Mind Club sign-in. How sign-in works

At a glance across your briefs

Erasca reports confirmed responses in 44% of 25 previously treated pancreatic cancer patients; Revolution Medicines reports 60.7% first line with chemotherapy. Stocks fell again on Thursday, and the VIX rose to 28.44.

XBI · 11.19
1D −0.6% · 1W −4.7% YTD +18.2%
144.12
IBB · 11.19
1D −0.8% · 1W −4.6% YTD +20.7%
203.72
UST 10-YEAR
11.19 · FROM 5.07% ON 11.18 2Y 4.76% · 2S10S +28BP
5.04%
US BIOTECH IPOS YTD
~$8.2B RAISED MIND CLUB TALLY · 11.20
30

Market figures as of the 11.19 close: XBI and IBB closes from Robinhood market data; Treasury yields from the U.S. Treasury daily par yield curve (11.19 and 11.18); IPO count and proceeds from the Mind Club financing tally (US sheet, IPOs of $5M or more, 11.20). SPY, IWM, fed funds and the VIX print in 01 Markets & outlook. Facts only, not a view on any security.

Verification at a glance

CLAIM CHECK
2 match · 2 partial · 1 open
5
CALENDAR DATES
confirmed at the source
18/22
REGISTRY WATCH
trials · 0 changes · full table in 14B
70
OPEN CALLS
none resolved today · see 15
3
CORRECTIONS
none new · see 16
17

The five-minute readThree that matter · one date · one open question

#What happenedSo what · our analysisPriority · sourcesPage
01Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint.Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027.Must read CoReg08
02Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months.Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.Must read CoReg08
03Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65.The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof.Must read CoReg09
+Also today. 04 Regeneron’s Livsayis (cemdisiran), an RNAi drug from Alnylam, was approved for generalized myasthenia gravis. 05 AbbVie took an option to license AND-gated bispecifics from DISCO, with $40M upfront; Bloomberg reports Sanofi is weighing a bid for Insmed.09
DATEOne date to hold. Fri 11.27: FDA goal date for BridgeBio’s BBP-418 in limb-girdle muscular dystrophy 2I/R9, per BridgeBio. More in 14.18
OPENThe open question. Does adding a pan-RAS drug to first-line chemotherapy help patients live longer? Both of today’s RAS results are single-arm; RASolute 303, randomized against chemotherapy alone with survival as a co-primary, is designed to test it for daraxonrasib; primary completion is estimated for 04.2028.17

HOW TO READ THIS BRIEF

Must readunderstand today. Know itsecondary. Scanawareness only. Verified a primary source was checked, Claim a company statement, Analysis our interpretation, Forecast a dated judgment with odds. Red boxes are the red team. Source badges: Reg trial registry Gov agency or government Peer peer-reviewed journal Pre preprint Co company or organizer release or filing Data curated database Press journalism. Claim Check verdicts compare a headline with the registered protocol: MatchPartialMismatchOpen. A verdict says what differs, never why.

Reading priority index

  • Must readERAS-0015 in pancreatic cancer · Daraxonrasib first line · Xanamem misses · Claim Check · Target Evidence Card
  • Know itLivsayis approval · AbbVie and DISCO, Sanofi and Insmed · Policy & regulatory watch · Verified Catalyst Calendar
  • ScanBright spot · Registry Watch · Public Calls Ledger